Logistics outsourcing company D. Logistics of Germany announced an agreement with Siemens Medical Engineering Group to start a new e-business venture in Europe’s medical market. Siemens will hold a 51% stake in the new company.The new company will
Logistics outsourcing company D. Logistics of Germany announced an agreement with Siemens Medical Engineering Group to start a new e-business venture in Europes medical market. Siemens will hold a 51% stake in the new company.
The new company will be aimed at establishing an electronic business communications platform for e-business between suppliers and customers in medical markets.
Using the new platform, hospitals, private medical practices, and pharmacies will be able to communicate via network channels with suppliers of their choice to speed orders for materials and medicines.
Siemens as a whole expects to soon be generating more than 25% of its total sales with e-business activity.
In addition to outsourcing optimizing logistics, D. Logistics sells B2B customers consulting services, temporary help, and tailored information technology. The company has 1200 employees and is headquartered in Leverkusen, Germany.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.